Table 2. Summary of cases of aseptic meningitis after mRNA (BNT162b2) vaccination against COVID-19.
| Clinical characteristics | 1st case [15] | 2nd case [16] | 3rd case [17] | 4th case [17] | 5th case (this case) | ||
|---|---|---|---|---|---|---|---|
| Age/Sex | 42/female | 18/male | 43/female | 38/female | 32/male | ||
| Onset time of symptoms | 1 week after 1st dose | 3 weeks after 2nd dose | 4 days after 2nd dose | 10 days after 1st dose | 2 weeks after 2nd dose | ||
| CSF analysis | |||||||
| WBC | 528/mm3 | 115/mm3 | 265/mm3 | 340/mm3 | 480/mm3 | ||
| Dominant cells | Monocyte (64.1%) | Monocyte (99.1%) | Lymphocyte (91.0%) | Lymphocyte (95.0%) | Lymphocyte (90.0%) | ||
| IgG antibody test | Positive | NA | Positive | Positive | Positive | ||
| Treatment | |||||||
| Antibacterial/antiviral agents | Acyclovir | Vancomycin/cefotaxime | Ceftriaxone/Acyclovir | No | Acyclovir | ||
| Final management | Methylprednisolone | Conservative management | Conservative management | Conservative management | Methylprednisolone | ||
| 500 mg/day for 5 days | 500 mg/day for 3 days | ||||||
| Nationality | Japan | Korea | Singapore | Singapore | Korea | ||
COVID-19, coronavirus disease 2019; CSF; cerebrospinal fluid, WBC; white blood cell, NA; not available.